제세동기 시장 : 유형별, 기술별, 환자 유형별, 최종 사용자별, 공급 채널별 시장 예측(2026-2032년)

The Defibrillators Market is projected to grow by USD 20.61 billion at a CAGR of 8.20% by 2032.

Defibrillators Market Executive Summary

The global defibrillators market is being reshaped by the urgent clinical need to improve survival from sudden cardiac arrest, a time-critical condition in which defibrillation is one of the few interventions that can directly restore a shockable rhythm. The American Heart Association has consistently emphasized that survival decreases by about 7% to 10% for every minute defibrillation is delayed when CPR is not provided, making device availability, usability, and response-system readiness central to market demand.

Growth is supported by rising cardiovascular disease burden, aging populations, broader public access defibrillation programs, and continued adoption of automated external defibrillators (AEDs), implantable cardioverter defibrillators (ICDs), wearable cardioverter defibrillators, and advanced hospital defibrillation systems. Buyers are prioritizing reliability, connectivity, battery performance, training support, and regulatory compliance as defibrillators move from specialized clinical environments into airports, schools, workplaces, public venues, ambulances, and home-care settings.

Transformative Shifts in the Defibrillators Landscape

The defibrillators landscape is shifting from reactive emergency equipment procurement toward integrated cardiac-response ecosystems. Public access AED deployment, dispatcher-assisted CPR, community responder apps, and EMS data integration are making defibrillation part of a broader survival chain rather than a standalone device purchase. This shift is especially important because early CPR and early defibrillation are consistently associated with better outcomes in out-of-hospital cardiac arrest.

Manufacturers are also responding to stricter quality expectations and post-market surveillance requirements. In the United States, defibrillators are regulated as medical devices by the FDA, and several product categories have faced heightened scrutiny due to recalls and performance risks. In Europe, the Medical Device Regulation has increased emphasis on clinical evidence, traceability, and post-market performance. These changes reward companies that can combine safety, usability, service readiness, and digital monitoring.

Cumulative Impact of Artificial Intelligence in Defibrillators

Artificial intelligence is becoming a cumulative force across defibrillator design, deployment, training, and service management. In clinical and emergency settings, AI-enabled analytics can support rhythm interpretation, artifact and noise reduction, CPR quality feedback, event documentation, and post-event review. These capabilities can help reduce cognitive load for responders while improving the consistency of data captured during resuscitation events.

AI also strengthens operational performance. Predictive maintenance algorithms can monitor battery health, electrode expiration, self-test results, and device readiness across large AED fleets in schools, airports, enterprises, and government facilities. For ICDs and wearable cardioverter defibrillators, AI-supported remote monitoring can help clinicians triage alerts and identify deterioration patterns. The opportunity is significant, but adoption depends on explainable algorithms, cybersecurity controls, regulatory validation, privacy protection, and evidence that AI improves workflow without delaying shocks.

Key Regional Insights

North America remains a leading defibrillators region due to mature EMS systems, public access AED initiatives, hospital investment, and high use of ICDs for patients at risk of life-threatening arrhythmias. The United States benefits from FDA oversight, established emergency medical services, and widespread cardiac resuscitation training, while Canada supports adoption through provincial public access defibrillation programs and workplace safety policies. Europe benefits from strong clinical guidelines, structured emergency-response networks, and regulatory modernization under the EU Medical Device Regulation, although compliance costs, clinical evidence requirements, and notified body capacity continue to influence product launches.

Asia-Pacific is expanding as cardiovascular disease burden, urbanization, hospital infrastructure, and government-led emergency preparedness programs increase demand for AEDs and advanced defibrillation systems. China, India, Japan, South Korea, and Australia are strengthening adoption through hospital upgrades, public access programs, and greater awareness of sudden cardiac arrest response. Latin America shows improving adoption in private hospitals, sports facilities, airports, and large employers, while access gaps remain in rural and public-sector settings. The Middle East is gaining momentum through healthcare modernization, emergency preparedness, and smart-city safety programs, particularly in high-income Gulf economies. Africa presents long-term potential as emergency-care capacity, training availability, ambulance systems, and donor-supported health infrastructure improve, although affordability and maintenance readiness remain critical barriers.

Key Group Insights

Across ASEAN, defibrillator adoption is supported by urban healthcare investment, medical tourism, airport safety programs, and expanding private hospital networks, while uneven EMS maturity creates opportunities for training-led AED deployment. The GCC is advancing through premium hospital infrastructure, public venue safety mandates, emergency preparedness initiatives, and national health strategies that prioritize digitally connected care. The European Union is shaped by harmonized medical device rules, guideline-driven resuscitation practice, and public access AED expansion across transportation hubs, schools, sports venues, and workplaces.

BRICS markets combine large cardiovascular disease burden with rising hospital capacity, creating scale opportunities but also pricing, reimbursement, and access challenges across urban and rural populations. G7 countries remain innovation leaders in ICDs, connected AED fleets, remote monitoring, and quality-assured resuscitation systems, supported by advanced reimbursement structures and mature clinical pathways. NATO members emphasize emergency readiness, military medicine, disaster response, and standardized response systems, which can support resilient defibrillator procurement for defense, public safety, and civilian emergency-care networks.

Key Country Insights

The United States leads through high AED visibility, strong cardiology infrastructure, FDA-regulated device pathways, and broad ICD utilization. Canada emphasizes public access defibrillation, workplace safety, and provincial EMS coordination, while Mexico and Brazil show demand momentum through private healthcare expansion, urban emergency programs, sports venue safety, and rising cardiovascular risk. In Europe, the United Kingdom, Germany, France, Italy, and Spain benefit from established resuscitation councils, hospital modernization, ambulance networks, and community AED initiatives, while Russia maintains demand through large hospital networks and emergency-care needs.

China and India represent major defibrillator adoption opportunities due to population scale, cardiovascular disease burden, expanding hospital systems, and growing awareness of sudden cardiac arrest response. Japan and South Korea show strong adoption of advanced cardiac technologies, supported by high hospital capability, aging populations, and public access AED placement in transport, education, and commercial environments. Australia combines robust EMS performance with public access AED deployment across community, sports, workplace, and commercial settings, reinforcing the role of early defibrillation in national cardiac arrest response.

Actionable Recommendations for Defibrillator Industry Leaders

Industry leaders should prioritize evidence-based device differentiation, focusing on shock accuracy, ease of use, multilingual guidance, ruggedness, battery longevity, cybersecurity, and readiness monitoring. In AEDs, growth will favor vendors that provide complete programs rather than devices alone, including placement analytics, responder training, maintenance services, compliance dashboards, and post-event data support.

Manufacturers should align product roadmaps with regulatory expectations in the FDA, EU MDR, and other major jurisdictions while investing in post-market surveillance and recall-prevention quality systems. Partnerships with EMS agencies, schools, employers, airports, sports organizations, and insurers can expand access and strengthen service-based engagement. For ICDs and wearable cardioverter defibrillators, leaders should strengthen remote monitoring, patient adherence support, and clinician workflow integration to improve outcomes and reduce alert fatigue.

Research Methodology

This executive summary is based on a structured research approach combining secondary research, regulatory review, clinical guideline assessment, and market triangulation. Sources considered include public information from the American Heart Association, European Resuscitation Council, World Health Organization, national health agencies, FDA medical device databases, medical device recall records, public procurement information, regulatory guidance, and peer-reviewed literature on cardiac arrest survival and defibrillation.

The methodology evaluates demand drivers across product categories, including AEDs, ICDs, wearable cardioverter defibrillators, manual external defibrillators, and hospital-based systems. Regional and country insights are assessed through healthcare infrastructure, cardiovascular disease burden, emergency-response maturity, regulatory frameworks, reimbursement conditions, public access programs, and technology adoption patterns. Findings are validated through cross-source comparison to reduce bias and ensure that conclusions remain data-backed and commercially relevant.

Conclusion

The defibrillators market is moving beyond hardware sales toward connected, service-driven cardiac emergency readiness. Demand is anchored in the proven importance of early defibrillation, growing cardiovascular disease burden, and the need for reliable devices across clinical, public, workplace, and home-care environments.

Future competitiveness will depend on regulatory discipline, clinical evidence, AI-enabled readiness, remote monitoring, cybersecurity, and partnerships that improve access and responder confidence. Organizations that combine trustworthy technology with training, maintenance, data integration, and outcome-focused deployment models will be best positioned as governments, healthcare systems, and enterprises invest in faster, more effective cardiac arrest response.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Definition
• 1.3. Market Segmentation & Coverage
• 1.4. Years Considered for the Study
• 1.5. Currency Considered for the Study
• 1.6. Language Considered for the Study
• 1.7. Key Stakeholders

2. Research Methodology

• 2.1. Introduction
• 2.2. Research Design
  • 2.2.1. Primary Research
  • 2.2.2. Secondary Research
• 2.3. Research Framework
  • 2.3.1. Qualitative Analysis
  • 2.3.2. Quantitative Analysis
• 2.4. Market Size Estimation
  • 2.4.1. Top-Down Approach
  • 2.4.2. Bottom-Up Approach
• 2.5. Data Triangulation
• 2.6. Research Outcomes
• 2.7. Research Assumptions
• 2.8. Research Limitations

3. Executive Summary

• 3.1. Introduction
• 3.2. CXO Perspective
• 3.3. Market Size & Growth Trends
• 3.4. Market Share Analysis, 2025
• 3.5. FPNV Positioning Matrix, 2025
• 3.6. New Revenue Opportunities
• 3.7. Next-Generation Business Models
• 3.8. Industry Roadmap

4. Market Overview

• 4.1. Introduction
• 4.2. Industry Ecosystem & Value Chain Analysis
  • 4.2.1. Supply-Side Analysis
  • 4.2.2. Demand-Side Analysis
  • 4.2.3. Stakeholder Analysis
• 4.3. Market Dynamics
  • 4.3.1. Key Drivers
  • 4.3.2. Key Restraints
  • 4.3.3. Key Opportunities
  • 4.3.4. Key Challenges
• 4.4. Porter's Five Forces Analysis
• 4.5. PESTLE Analysis
• 4.6. Market Outlook
  • 4.6.1. Near-Term Market Outlook (0-2 Years)
  • 4.6.2. Medium-Term Market Outlook (3-5 Years)
  • 4.6.3. Long-Term Market Outlook (5-10 Years)
• 4.7. Go-to-Market Strategy

5. Market Insights

• 5.1. Consumer Insights & End-User Perspective
• 5.2. Consumer Experience Benchmarking
• 5.3. Opportunity Mapping
• 5.4. Distribution Channel Analysis
• 5.5. Pricing Trend Analysis
• 5.6. Regulatory Compliance & Standards Framework
• 5.7. ESG & Sustainability Analysis
• 5.8. Disruption & Risk Scenarios
• 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Defibrillators Market, by Type

• 7.1. External Defibrillators
  • 7.1.1. Automated External Defibrillators (AED)
  • 7.1.2. Manual External Defibrillators
  • 7.1.3. Wearable Cardioverter Defibrillators
• 7.2. Implantable Cardioverter Defibrillators (ICD)
  • 7.2.1. Dual-Chamber ICDs
  • 7.2.2. Single-Chamber ICDs
  • 7.2.3. Subcutaneous ICDs

8. Defibrillators Market, by Technology

• 8.1. Biphasic Technology
• 8.2. Monophasic Technology

9. Defibrillators Market, by Patient Type

• 9.1. Adult Patients
• 9.2. Pediatric Patients

10. Defibrillators Market, by End User

• 10.1. Hospitals
• 10.2. Pre-Hospital Care Providers
• 10.3. Public & Community Access

11. Defibrillators Market, by Supply Channel

• 11.1. Offline Retails
• 11.2. Online Platforms

12. Defibrillators Market, by Region

• 12.1. Asia-Pacific
• 12.2. North America
• 12.3. Latin America
• 12.4. Europe
• 12.5. Middle East
• 12.6. Africa

13. Defibrillators Market, by Group

• 13.1. ASEAN
• 13.2. GCC
• 13.3. European Union
• 13.4. BRICS
• 13.5. G7
• 13.6. NATO

14. Defibrillators Market, by Country

• 14.1. United States
• 14.2. Canada
• 14.3. Mexico
• 14.4. Brazil
• 14.5. United Kingdom
• 14.6. Germany
• 14.7. France
• 14.8. Russia
• 14.9. Italy
• 14.10. Spain
• 14.11. China
• 14.12. India
• 14.13. Japan
• 14.14. Australia
• 14.15. South Korea

15. Competitive Landscape

• 15.1. Market Concentration Analysis, 2025
  • 15.1.1. Concentration Ratio (CR)
  • 15.1.2. Herfindahl Hirschman Index (HHI)
• 15.2. Recent Developments & Impact Analysis, 2025
• 15.3. Product Portfolio Analysis, 2025
• 15.4. Benchmarking Analysis, 2025

16. Company Profiles

• 16.1. Abbott Laboratories
• 16.2. AMI Italia S.r.l.
• 16.3. Avive Solutions Inc.
• 16.4. Biotronik SE & CoKG
• 16.5. Boston Scientific Corporation
• 16.6. CU Medical Systems, Inc.
• 16.7. GE HealthCare Technologies Inc.
• 16.8. Koninklijke Philips N.V.
• 16.9. Mediana Co., Ltd.
• 16.10. Medtonic PLC
• 16.11. Metsis Medikal
• 16.12. MicroPort Scientific Corporation
• 16.13. Narang Medical Limited
• 16.14. Nihon Kohden Corporation
• 16.15. OIARSO S COOP
• 16.16. Progetti Srl
• 16.17. Schiller AG
• 16.18. Shenzhen Mindray Bio-Medical Electronics Co., Ltd.
• 16.19. Stryker Corporation
• 16.20. Thermo Fisher Scientific Inc.
• 16.21. Weinmann Emergency Medical Technology GmbH + Co. KG
• 16.22. ZOLL Medical Corporation by Asahi Kasei Corporation